598 related articles for article (PubMed ID: 31173856)
1. Akt in cancer: Mediator and more.
Revathidevi S; Munirajan AK
Semin Cancer Biol; 2019 Dec; 59():80-91. PubMed ID: 31173856
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of PI3K/AKT in tumor-related epigenetic regulation.
Yang Q; Jiang W; Hou P
Semin Cancer Biol; 2019 Dec; 59():112-124. PubMed ID: 30951826
[TBL] [Abstract][Full Text] [Related]
3. Targeting AKT/PKB to improve treatment outcomes for solid tumors.
Iida M; Harari PM; Wheeler DL; Toulany M
Mutat Res; 2020; 819-820():111690. PubMed ID: 32120136
[TBL] [Abstract][Full Text] [Related]
4. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
Carnero A; Blanco-Aparicio C; Renner O; Link W; Leal JF
Curr Cancer Drug Targets; 2008 May; 8(3):187-98. PubMed ID: 18473732
[TBL] [Abstract][Full Text] [Related]
5. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
Ediriweera MK; Tennekoon KH; Samarakoon SR
Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
[TBL] [Abstract][Full Text] [Related]
6. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
7. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.
Toulany M; Rodemann HP
Semin Cancer Biol; 2015 Dec; 35():180-90. PubMed ID: 26192967
[TBL] [Abstract][Full Text] [Related]
8. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
[TBL] [Abstract][Full Text] [Related]
9. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
10. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
11. Receptor tyrosine kinases in PI3K signaling: The therapeutic targets in cancer.
Jiang W; Ji M
Semin Cancer Biol; 2019 Dec; 59():3-22. PubMed ID: 30943434
[TBL] [Abstract][Full Text] [Related]
12. Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?
Singh SS; Yap WN; Arfuso F; Kar S; Wang C; Cai W; Dharmarajan AM; Sethi G; Kumar AP
World J Gastroenterol; 2015 Nov; 21(43):12261-73. PubMed ID: 26604635
[TBL] [Abstract][Full Text] [Related]
13. PI3K/PTEN signaling in tumorigenesis and angiogenesis.
Jiang BH; Liu LZ
Biochim Biophys Acta; 2008 Jan; 1784(1):150-8. PubMed ID: 17964232
[TBL] [Abstract][Full Text] [Related]
14. [PI3K-AKT-mTOR pathway inhibitors].
Cortot A; Armand JP; Soria JC
Bull Cancer; 2006 Jan; 93(1):19-26. PubMed ID: 16455502
[TBL] [Abstract][Full Text] [Related]
15. Cross-talk between the CK2 and AKT signaling pathways in cancer.
Ruzzene M; Bertacchini J; Toker A; Marmiroli S
Adv Biol Regul; 2017 May; 64():1-8. PubMed ID: 28373060
[TBL] [Abstract][Full Text] [Related]
16. Glycogen synthase kinases: Moonlighting proteins with theranostic potential in cancer.
Nagini S; Sophia J; Mishra R
Semin Cancer Biol; 2019 Jun; 56():25-36. PubMed ID: 29309927
[TBL] [Abstract][Full Text] [Related]
17. Targeting Akt in cancer for precision therapy.
Hua H; Zhang H; Chen J; Wang J; Liu J; Jiang Y
J Hematol Oncol; 2021 Aug; 14(1):128. PubMed ID: 34419139
[TBL] [Abstract][Full Text] [Related]
18. PI3K/Akt signalling pathway and cancer.
Fresno Vara JA; Casado E; de Castro J; Cejas P; Belda-Iniesta C; González-Barón M
Cancer Treat Rev; 2004 Apr; 30(2):193-204. PubMed ID: 15023437
[TBL] [Abstract][Full Text] [Related]
19. The quinoline imidoselenocarbamate EI201 blocks the AKT/mTOR pathway and targets cancer stem cells leading to a strong antitumor activity.
Ibáñez E; Agliano A; Prior C; Nguewa P; Redrado M; González-Zubeldia I; Plano D; Palop JA; Sanmartín C; Calvo A
Curr Med Chem; 2012; 19(18):3031-43. PubMed ID: 22455594
[TBL] [Abstract][Full Text] [Related]
20. PI3K and AKT: Unfaithful Partners in Cancer.
Faes S; Dormond O
Int J Mol Sci; 2015 Sep; 16(9):21138-52. PubMed ID: 26404259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
